Eiger BioPharmaceuticals, Inc.: Nasdaq/NYSE listing notice — Eiger BioPharma receives Nasdaq equity deficiency notice; delisting risk elevated

Eiger BioPharmaceuticals, Inc.

Received Nasdaq deficiency letter on Nov 10, 2023 for failing $10M stockholders' equity requirement.
Must submit compliance plan by Dec 26, 2023; if accepted, extension to May 8, 2024.
Also has bid price deficiency (below $1.00) with compliance deadline Jan 22, 2024; likely ineligible for extra extension due to equity shortfall.
Stock continues trading under EIGR on Nasdaq pending potential delisting appeals.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Eiger BioPharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A), 5450(b)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5450(b)(1)(A), 5450(b)

Exact text from the filing

November 10, 2023, Eiger BioPharmaceuticals, Inc. (“Eiger”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying Eiger that it no longer satisfies the $10 million stockholders’ equity requirement for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(1)(A), or the alternatives to that requirement - a $50 million market value of listed securities or $50 million in net income in the most recent fiscal year or two of the last three fiscal years - as required by Nasdaq Listing Ru

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-275985

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.